Patents by Inventor Stephan R. Targan

Stephan R. Targan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120208900
    Abstract: The present invention relates to methods of predicting susceptibility to a severe form of Crohn's disease in an individual by determining the presence or absence of one or more risk variants. In one embodiment, the risk variants comprise a combination of genetic risk variants and clinical risk factors. In another embodiment, the genetic risk variants are at the IL12B genetic locus. In another embodiment, the severe form of Crohn's disease is characterized by a rapid progression to a condition requiring surgery for treatment.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Marla C. Dubinsky, Dermot P. McGovern, Jerome I. Rotter, Stephan R. Targan
  • Patent number: 8153443
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: April 10, 2012
    Assignees: Cedars-Sinai Medical Center, The UAB Research Foundation
    Inventors: Kent D. Taylor, Jerome I. Rotter, Charles O. Elson, Stephan R. Targan
  • Publication number: 20120073585
    Abstract: The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.
    Type: Application
    Filed: April 8, 2010
    Publication date: March 29, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • Publication number: 20120053131
    Abstract: Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
    Type: Application
    Filed: December 24, 2009
    Publication date: March 1, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan, Talin Haritunians, Dermot P. McGovern, Xiuqing Guo
  • Publication number: 20120041082
    Abstract: Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci.
    Type: Application
    Filed: January 13, 2010
    Publication date: February 16, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan
  • Publication number: 20110229471
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 22, 2011
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Patent number: 7993866
    Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: August 9, 2011
    Assignees: Cedars-Sinai Medical Center, The Regents of the University of California
    Inventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
  • Patent number: 7993865
    Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: August 9, 2011
    Assignees: Cedars-Sinai Medical Center, The Regents of the University of California
    Inventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
  • Patent number: 7993867
    Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: August 9, 2011
    Assignees: Cedars-Sinai Medical Center, The Regents of the University of California
    Inventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
  • Publication number: 20110189685
    Abstract: The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2.
    Type: Application
    Filed: October 22, 2009
    Publication date: August 4, 2011
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kent D. Taylor, Jerome I. Rotter, Ling Mei, Stephan R. Targan
  • Publication number: 20110177969
    Abstract: The present invention relates to methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility variants at the IL17RD locus. in one embodiment, the present invention provides a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease.
    Type: Application
    Filed: October 1, 2009
    Publication date: July 21, 2011
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan, Dermot P. McGovern, Ling Mei
  • Publication number: 20110124644
    Abstract: Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included
    Type: Application
    Filed: May 20, 2009
    Publication date: May 26, 2011
    Applicants: CEDARS-SINAI MEDICAL CENTER, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor, David Ziring, Jonathan Braun, Bo Wei
  • Publication number: 20110117552
    Abstract: The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2/CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease.
    Type: Application
    Filed: October 11, 2010
    Publication date: May 19, 2011
    Applicant: Cedars-Sinai Medical Center
    Inventors: Kent D. Taylor, Jerome I. Rotter, Huiying Yang, Kazuhito Sugimura, Stephan R. Targan
  • Patent number: 7838239
    Abstract: A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: November 23, 2010
    Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Research Center, Inc., Cedars-Sinai Medical Center
    Inventors: Masato Mitsuhashi, Stephan R. Targan
  • Publication number: 20100284999
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 11, 2010
    Applicants: CEDARS-SINAI MEDICAL CENTER, THE UAB RESEARCH FOUNDATION
    Inventors: Kent D. Taylor, Jerome I. Rotter, Charles O. Elson, Stephan R. Targan
  • Publication number: 20100240043
    Abstract: The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus.
    Type: Application
    Filed: October 20, 2008
    Publication date: September 23, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan, Dermot P. McGovern, Ling Mei, Xiaowen Su
  • Publication number: 20100240077
    Abstract: The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.
    Type: Application
    Filed: December 22, 2009
    Publication date: September 23, 2010
    Applicant: Cedars-Sinai Medical Center
    Inventors: Stephan R. Targan, Eric A. Vasiliauskas, William S. Mow, Huiying Yang, Phillip R. Fleshner, Jerome I. Rotter
  • Patent number: 7790370
    Abstract: The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: September 7, 2010
    Assignee: Cedars-Sinai Medical Center
    Inventors: Maria T. Abreu, Kent D. Taylor, Jerome I. Rotter, Huiying Yang, Stephan R. Targan
  • Publication number: 20100190162
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
    Type: Application
    Filed: February 26, 2008
    Publication date: July 29, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • Publication number: 20100144903
    Abstract: In one embodiment, this invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of risk haplotypes in IL23R, IL17A, IL17RA and/or IL12RB1 locus. In another embodiment, the invention provides methods of diagnosing and/or predicting susceptibility to Crohn's Disease in an individual by determining the presence or absence of risk haplotype at the IL12RB2 locus.
    Type: Application
    Filed: May 2, 2008
    Publication date: June 10, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kent D. Taylor, Jerome I. Rotter, Stephan R. Targan